MARKET

CSTL

CSTL

Castle
NASDAQ

Real-time Quotes | Nasdaq Last Sale

51.86
+0.79
+1.55%
Opening 15:34 12/04 EST
OPEN
51.31
PREV CLOSE
51.07
HIGH
52.02
LOW
51.26
VOLUME
207.11K
TURNOVER
--
52 WEEK HIGH
55.31
52 WEEK LOW
21.01
MARKET CAP
1.03B
P/E (TTM)
-325.3450
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Castle Biosciences Highlights Publication Of Peer-Reviewed Publication Demonstrating Clinical Impact Of DecisionDx-Melanoma
Study published in Future Oncology Castle Biosciences, Inc. (NASDAQ:CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced the
Benzinga · 8h ago
Castle Biosciences Announces Publication of Peer-Reviewed Publication Demonstrating the Clinical Impact of DecisionDx®-Melanoma
Business Wire · 8h ago
Castle Biosciences to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference
Business Wire · 11/23 22:00
Castle Biosciences to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference
Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that management will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference, December 1-3, 2020. Derek Maetzold, president and chief executive officer, and Frank Stokes, chief financial officer, will provide a pre-recorded investor presentation and will be available for virtual one-on-one investor meetings during the conference.
BusinessWire · 11/23 19:00
Castle Biosciences Announces Publication of Clinical Validation and Utility Data for DecisionDx® DiffDx-Melanoma for Suspicious Pigmented Lesions
Castle Biosciences Announces Publication of Clinical Validation and Utility Data for DecisionDx® DiffDx™-Melanoma for Suspicious Pigmented Lesions.
Business Wire · 11/17 12:00
Castle Biosciences Announces Publication of Clinical Validation and Utility Data for DecisionDx(R) DiffDx(TM)-Melanoma for Suspicious Pigmented Lesions
Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced the publication of two studies in SKIN: The Journal of Cutaneous Medicine, which demonstrated that DecisionDx(R) DiffDx(TM)-Melanoma adds significant diagnostic clarity for physicians when characterizing difficult-to-diagnose melanocytic lesions and establishes clinical utility with the potential to improve patient care.
BusinessWire · 11/17 09:00
Zacks.com featured highlights include: Catalyst Biosciences, UFP Industries, VeriSign, InMode and Castle Biosciences
Zacks.com featured highlights include: Catalyst Biosciences, UFP Industries, VeriSign, InMode and Castle Biosciences
Zacks · 11/12 13:50
Castle Biosciences Presents Data on DecisionDx®-Melanoma and DecisionDx® DiffDx-Melanoma Tests at American Society of Dermatopathology (ASDP) 57th Virtual Annual Meeting
Castle today announced the presentation of data on two of its skin cancer gene expression profile tests during the 57th Meeting of ASDP.
Business Wire · 11/12 12:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CSTL. Analyze the recent business situations of Castle through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CSTL stock price target is 60.40 with a high estimate of 70.00 and a low estimate of 54.00.
EPS
Institutional Holdings
Institutions: 164
Institutional Holdings: 13.47M
% Owned: 67.67%
Shares Outstanding: 19.91M
TypeInstitutionsShares
Increased
63
2.36M
New
39
179.65K
Decreased
36
886.61K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
+1.44%
Healthcare Equipment & Supplies
+1.17%
Key Executives
Chairman/Independent Director
Daniel Bradbury
President/Chief Executive Officer/Founder/Director
Derek Maetzold
Chief Financial Officer/Primary Contact
Frank Stokes
Senior Vice President/Director of Sales
Toby Juvenal
Senior Vice President
Kristen Oelschlager
Vice President/Director of Marketing
Alice Izzo
Vice President - Research & Development
Bob Cook
Other
Michael Maltby
Other
Noreen Manning
Other
Bernhard Spiess
Independent Director
Mara Aspinall
Independent Director
G. Bradley Cole
Independent Director
Joseph Cook
Independent Director
Miles Harrison
Independent Director
David Kabakoff
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About CSTL
Castle Biosciences, Inc. is a commercial-stage dermatological cancer company. The Company is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The Company has two market proprietary products, DecisionDx-Melanoma and DecisionDx-UM, and have two active proprietary products in development DecisionDx-UM and DecisionDx-Melanoma. The Company is developing a treatment plan for certain cancers using clinical and pathology factors. Its lead product, DecisionDx-Melanoma, is a proprietary multi-gene expression profile (GEP), a test that predicts the risk of metastasis or recurrence for patients diagnosed with invasive cutaneous melanoma, a deadly skin cancer.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Castle Biosciences Inc stock information, including NASDAQ:CSTL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CSTL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CSTL stock methods without spending real money on the virtual paper trading platform.